Oklahoma; tUniversity M e d i c a l Center, Jacksonville, Florida, ~Rhi%e-Poulenc Rorer Research and Development, Collegeville, P e~s y h n i a , USA Summary:This multicenter, open-label, single crossover study examined 195 patients taking an immediate-release diltiazem tablet as chronic stable angina therapy to determine if apparently logical methods of converting them to an extended-release, oncedaily formulation were effective. Patients were converted from the immediate-release (Phase I) to an extendedrelease (Phase II) formulation of diltiazem on a mg-for-mg basis or, when a similar dose was not available, to the next higher exercise testing at the end of each phase, and ambulatory electrocardiographic monitoring (AEM) during the week prior to the exercise study were evaluated. There was a statistically significant decrease in angina frequency and nitroglycerin consumption during Phase II. In the exercise studies, there was an insigdicant increase in time to 1 mm ST-segment depression and total exercise time associated with a statistically significantly lower end-exexise blood pressure and heart rate in phase II. In those patients who had ischemia during either phase on AEM, total ischemic duration and ischemic episodes were insigruficantly lower in Phase II. All observations were similar in the subgroup of patients who were converted mg-for-mg. Adverse reactions were equal. Thus, in converting patients from an immediate-to an extended-release diltiazem formulation for the treatment of symptomatic coronary artery disease, it is reasonable to convert directly to the same or, if not available, the next higher available dose of the extended-release preparation.12omgmg. weekly anginaoccurrencesandni~y&use,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.